MCID: BCT006
MIFTS: 42

Bacterial Conjunctivitis

Categories: Eye diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Bacterial Conjunctivitis

MalaCards integrated aliases for Bacterial Conjunctivitis:

Name: Bacterial Conjunctivitis 11 14 16 71
Conjunctivitis, Bacterial 43
Purulent Conjunctivitis 11

Classifications:



External Ids:

Disease Ontology 11 DOID:9700
MeSH 43 D003234
NCIt 49 C53656
SNOMED-CT 68 193877001
ICD10 31 H10.0
UMLS 71 C0009768

Summaries for Bacterial Conjunctivitis

MalaCards based summary: Bacterial Conjunctivitis, also known as conjunctivitis, bacterial, is related to conjunctivitis and haemophilus influenzae. An important gene associated with Bacterial Conjunctivitis is ITPKC (Inositol-Trisphosphate 3-Kinase C), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PAK Pathway. The drugs Moxifloxacin and Ethinylestradiol have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and neutrophil.

Related Diseases for Bacterial Conjunctivitis

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis Rare Conjunctivitis

Diseases related to Bacterial Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 953)
# Related Disease Score Top Affiliating Genes
1 conjunctivitis 31.9 TNF IL6 IL10 CXCL8
2 haemophilus influenzae 31.0 TNF IL1B CXCL8
3 corneal ulcer 30.2 TNF IL6 IL1B
4 ophthalmia neonatorum 30.1 MTRR CEACAM3 CD4
5 trachoma 29.9 TNF IL6 IL10
6 eyelid disease 29.8 TNF IL6 CD4
7 keratitis, hereditary 29.7 TNF IL6 IL1B IL10 CXCL8 CD4
8 blepharitis 29.7 TNF IL6 IL1B CXCL8 CD4
9 chlamydia 29.6 TNF IL6 IL1B IL10 CXCL8 CRP
10 purpura 29.3 TNF IL6 IL1B IL10 CXCL8 CRP
11 endophthalmitis 29.1 TNF IL6 IL1B CXCL8 CRP CD4
12 chronic conjunctivitis 29.1 TNF IL6 IL1B IL10 CXCL8 CD4
13 meningitis 29.1 TNF IL6 IL1B IL10 CXCL8 CRP
14 allergic conjunctivitis 28.9 TNF IL6 IL1B IL10 CXCL8 CD4
15 iridocyclitis 28.9 TNF IL6 IL1B IL10 CXCL8 CRP
16 anterior uveitis 28.9 TNF IL6 IL1B IL10 CXCL8 CRP
17 otitis media 28.6 TNF IL6 IL1B IL10 GPT CXCL8
18 eye disease 28.2 TNF IL6 IL1B IL10 GPT CXCL8
19 skin disease 28.0 TNF IL6 IL1B IL10 GPT CXCL8
20 disease by infectious agent 27.9 TNF IL6 IL1B IL10 GPT CXCL8
21 acute conjunctivitis 10.5
22 noma 10.3 CXCL8 ALB
23 chronic duodenal ileus 10.3 CRP ALB
24 external pathological resorption 10.3 TNF IL6
25 ankylosing spondylitis 3 10.3 CRP ALB
26 renal tuberculosis 10.3 CRP ALB
27 anterior scleritis 10.3 TNF CRP
28 chronic intestinal vascular insufficiency 10.3 CRP ALB
29 acute vascular insufficiency of intestine 10.3 CRP ALB
30 peptic ulcer perforation 10.3 CRP ALB
31 posterior scleritis 10.3 TNF CRP
32 tuberculous peritonitis 10.3 CRP ALB
33 rheumatoid arthritis interstitial lung disease 10.3 TNF CRP
34 superior mesenteric artery syndrome 10.3 CRP ALB
35 gastric dilatation 10.3 CRP ALB
36 chronic orbital inflammation 10.3 TNF CRP
37 senile entropion 10.3 TNF CXCL8
38 null-cell leukemia 10.3 TNF IL6
39 erythema elevatum diutinum 10.3 CXCL8 CRP
40 interstitial keratitis 10.3 TNF CRP
41 ureterolithiasis 10.3 CRP ALB
42 chronic salpingitis 10.2 TNF CEACAM3
43 non-syndromic x-linked intellectual disability 96 10.2 IL1B ALB
44 periodontitis, chronic 10.2 IL6 IL1B
45 epididymo-orchitis 10.2 IL6 CRP
46 generalized atherosclerosis 10.2 IL6 CRP ALB
47 hemopericardium 10.2 NPPB CRP
48 osteosclerotic myeloma 10.2 IL6 IL1B
49 intracranial embolism 10.2 IL6 CRP ALB
50 alveolar periostitis 10.2 TNF IL6 CRP

Graphical network of the top 20 diseases related to Bacterial Conjunctivitis:



Diseases related to Bacterial Conjunctivitis

Symptoms & Phenotypes for Bacterial Conjunctivitis

Drugs & Therapeutics for Bacterial Conjunctivitis

Drugs for Bacterial Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Moxifloxacin Approved, Investigational Phase 4 186826-86-8, 354812-41-2, 151096-09-2 152946
2
Ethinylestradiol Approved Phase 4 57-63-6 5991
3
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
4
Polyestradiol phosphate Approved Phase 4 28014-46-2
5
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
6 Contraceptives, Oral, Combined Phase 4
7 Contraceptives, Oral Phase 4
8 Contraceptive Agents Phase 4
9 Estradiol 3-benzoate Phase 4
10 Estradiol 17 beta-cypionate Phase 4
11 Norgestimate, ethinyl estradiol drug combination Phase 4
12
Framycetin Approved, Experimental, Vet_approved Phase 3 1404-04-2, 3947-65-7, 119-04-0 413349 8378
13
Polymyxin B Approved, Vet_approved Phase 3 1405-20-5, 1404-26-8 4868
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
16
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
17
Ofloxacin Approved Phase 3 82419-36-1 4583
18
Iodine Approved, Investigational Phase 3 7553-56-2 807
19
Povidone-iodine Approved Phase 3 25655-41-8
20
Povidone K30 Approved, Experimental Phase 3 9003-39-8 6917 131751496
21
Tobramycin Approved, Investigational Phase 3 32986-56-4 36294
22
Sorbitol Approved, Investigational Phase 3 69-65-8, 50-70-4 453 6251 5780
23
Pentetic acid Approved Phase 3 67-43-6
24
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
25
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 3 62-33-9, 60-00-4 6049
26
Calcium polycarbophil Approved Phase 3 126040-58-2
27
Vancomycin Approved Phase 3 1404-90-6 14969
28
Gatifloxacin Approved, Investigational Phase 3 112811-59-3 5379
29
Besifloxacin Approved Phase 3 141388-76-3 22743624 10178705
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
31
Cadexomer iodine Experimental Phase 3 94820-09-4
32
Pazufloxacin Investigational Phase 3 127045-41-4 465466
33 Dexamethasone, neomycin, polymyxin B drug combination Phase 3
34 Polymyxins Phase 3
35 glucocorticoids Phase 3
36 Hormones Phase 3
37 Tobramycin, Dexamethasone Drug Combination Phase 3
38 Hormone Antagonists Phase 3
39 Anti-Inflammatory Agents Phase 3
40 Cytochrome P-450 Enzyme Inhibitors Phase 3
41 Citrate Phase 3
42 Psyllium Phase 3
43 Fluoroquinolones Phase 3
44 Antitubercular Agents Phase 3
45
Dipivefrin Approved Phase 2 52365-63-6 3105
46
Hyaluronic acid Approved, Vet_approved Phase 2 9004-61-9 53477741
47 Adjuvants, Immunologic Phase 2
48 Protective Agents Phase 2
49 Viscosupplements Phase 2
50 Immunologic Factors Phase 2

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
2 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
3 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
4 Randomized Clinical Trial Of Drug Topics Efficacy Maxinom® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Union Chemical) And Maxitrol® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Alcon) In Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis Unknown status NCT01227863 Phase 3 MAXINOM®;Maxitrol®
5 RANDOMIZED CLINICAL EVALUATION OF EFFECTIVENESS COMPARISON BETWEEN DRUGS OPHTHALMOLOGICAL TOBRACORT® (TOBRAMYCIN + DEXAMETHASONE - LAB. UNIÃO QUÍMICA)AND TOBRADEX® (TOBRAMYCIN + DEXAMETHASONE - LAB. ALCON) IN REDUCING THE SIGNS AND SYMPTOMS OF ACUTE BACTERIAL CONJUNCTIVITIS Unknown status NCT01227915 Phase 3 Tobracort;Tobradex
6 Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis Completed NCT00759148 Phase 3 Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%
7 An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients Completed NCT01573910 Phase 3 Moxifloxacin ophthalmic solution, 0.5%;Ofloxacin ophthalmic solution, 0.3%
8 A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis Completed NCT03004924 Phase 3 SHP640;PVP-I 0.6%;Placebo
9 A Single- Centre, Randomised Study Of The Clinical And Microbiological Efficacy Of Decreasing The Dosage Of Levofloxacin 0,5% Eye Drops As Compared To Standard Eye Drop Dosage In Patients With Bacterial Conjunctivitis Completed NCT00565123 Phase 2, Phase 3 0.5% levofloxacin eye drops
10 A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0 % AzaSite Compared to Vehicle in the Treatment of Bacterial Conjunctivitis Completed NCT00105534 Phase 3 AzaSite
11 A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0% AzaSite Compared to 0.3% Tobramycin Ophthalmic Solution in the Treatment of Bacterial Conjunctivitis Completed NCT00105469 Phase 3 AzaSite;Tobramycin
12 A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis. Completed NCT00972777 Phase 2, Phase 3 Besifloxacin;Vehicle (Placebo)
13 Clinical Efficacy and Safety of T1225 1.5% Eye Drops (3-Day Treatment) Versus Tobramycin 0.3 % Eye Drops (7-Day Treatment) in the Treatment of Purulent Bacterial Conjunctivitis Completed NCT00357773 Phase 3 Azithromycin (T1225)
14 A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis. Completed NCT00347932 Phase 3 ISV-403;Vehicle
15 Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children. Completed NCT01155999 Phase 3 T1225;Tobramycin
16 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00518089 Phase 3 Gatifloxacin 0.5% eye drops;placebo eye drops
17 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00509873 Phase 3 Gatifloxacin 0.5% eye drops;placebo eye drops
18 A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis Completed NCT00348348 Phase 3 Besifloxacin;Moxifloxacin solution
19 An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in India Completed NCT00332293 Phase 3 Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%;Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
20 AL-15469A for the Treatment of Bacterial Conjunctivitis Completed NCT00331916 Phase 3 quinolone
21 A Randomized, Multicenter, Double-Masked, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Vancomycin Hydrochloride Ophthalmic Ointment 1.1% in Patients With Moderate to Severe Bacterial Conjunctivitis Completed NCT02432807 Phase 3 Vancomycin 1.1%;Placebo
22 A Study to Evaluate the Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Following Three Times Daily(TID) Dosing for 7 Days Completed NCT01175590 Phase 3 Besivance;Vehicle
23 A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis Terminated NCT01740388 Phase 3 Besifloxacin;Vehicle
24 Clinical Study of the Efficacy of the Ophthalmic Solution of Pazufloxacin 0.6% (PRO-157) for the Treatment of Acute Bacterial Conjunctivitis, Compared to the Ophthalmic Solution of Gatifloxacin 0.3%. Terminated NCT03696342 Phase 3 Pazufloxacin;Zymar
25 Evaluation of the Safety and Efficacy of Topical Besifloxacin Ophthalmic Suspension, 0.6% Compared With Gatifloxacin, 0.3% Ophthalmic Solution for the Treatment of Presumed Bacterial Conjunctivitis in Subjects From Birth to 31 Days of Age Terminated NCT01330355 Phase 3 Besivance;Gatifloxacin
26 Association of Azithromycin 1,5%/Loteprednol 0,5% Eye Drops Versus Individual Administration of Azithromycin 1,5% and Loteprednol 0,5% in the Treatment of Ocular Inflammation and Infection Withdrawn NCT01721694 Phase 3 azithromycin 1.5%/Loteprednol 0,5% + placebo;azithromycin 1.5% + Loteprednol 0,5% (separately)
27 A Randomized, Double Blind, Phase II Multicenter Trial to Evaluate the Safety and Efficacy of PRO-157 Ophthalmic Solution in Three Different Dosing Regimen Versus Moxifloxacin Versus Gatifloxacin in Patients With Bacterial Conjunctivitis. Completed NCT02980523 Phase 2 PRO-157;Vigamox;Zymar®;Lagricel Ofteno®
28 A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis Completed NCT00622908 Phase 2 ISV-403;Vehicle
29 A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis Completed NCT01877694 Phase 2 Auriclosene Solution 0.3%;Auriclosene Vehicle
30 Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis Withdrawn NCT01238783 Phase 2 AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension;AL-15469A 0.5%;AL-6515 0.3%;Vehicle
31 Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers Unknown status NCT03235141 Phase 1 azithromycin eye drops by essex;azithromycin eye drops
32 Systemic Pharmacokinetics of BOL-303224-A After Single and Multiple Instillations of BOL-303224-A in Subjects With Suspected Bacterial Conjunctivitis Completed NCT00407589 Phase 1 BOL-303224-A
33 Phase I Clinical Trial, to Evaluate the Safety and Tolerability of the Ophthalmic Solution PRO-174 Versus Sophixín Ofteno®, Elaborated by Laboratorios Sophia on the Ocular Surface of Ophthalmological and Clinically Healthy Subjects Completed NCT03519516 Phase 1 PRO-174;Sophixín Ofteno®
34 Study to Evaluate the Safety and Tolerability of Pro-143 Ophthalmic Solution in Healthy Volunteers. Withdrawn NCT03698045 Phase 1 PRO-143 Ophthalmic Solution
35 Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking Ophthalmologists Completed NCT03987178

Search NIH Clinical Center for Bacterial Conjunctivitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ciprofloxacin
Loteprednol
loteprednol etabonate

Cochrane evidence based reviews: conjunctivitis, bacterial

Genetic Tests for Bacterial Conjunctivitis

Anatomical Context for Bacterial Conjunctivitis

Organs/tissues related to Bacterial Conjunctivitis:

MalaCards : Eye, Skin, Neutrophil, Kidney

Publications for Bacterial Conjunctivitis

Articles related to Bacterial Conjunctivitis:

(show top 50) (show all 595)
# Title Authors PMID Year
1
Universal newborn eye screening: a systematic review of the literature and review of international guidelines. 62
36269293 2022
2
Adult Eye Conditions: Common Eye Conditions. 62
35947131 2022
3
Five-year review of ocular Neisseria gonorrhoeae infections presenting to ophthalmology departments in Greater Glasgow & Clyde, Scotland. 62
34211138 2022
4
Indication-prescription study for the management of conjunctivitis in a Colombian population. 62
35776393 2022
5
Ciprofloxacin-Loaded Zein/Hyaluronic Acid Nanoparticles for Ocular Mucosa Delivery. 62
35893813 2022
6
A qualitative evaluation of pediatric conjunctivitis medical decision making and opportunities to improve care. 62
35421542 2022
7
Survey of state conjunctivitis policies for school-age students. 62
35378302 2022
8
Successful use of tofacitinib in reactive arthritis refractory to conventional therapies - a case series. 62
35024869 2022
9
Does This Patient With Acute Infectious Conjunctivitis Have a Bacterial Infection?: The Rational Clinical Examination Systematic Review. 62
35699701 2022
10
Cytological and microbiological evaluation of conjunctiva in camels with and without conjunctivitis. 62
35657141 2022
11
Spectrum and resistance in bacterial infections of the ocular surface in a German tertiary referral center 2009-2019. 62
35687174 2022
12
Multisystem inflammatory syndrome in children (MIS-С) associated with SARS-CoV-2 infection and severe abdominal syndrome. The Lviv "OHMATDYT" (Western Ukraine) experience. 62
35511674 2022
13
Safety of topical ophthalmic antibiotics in pregnant women with hordeola, chalazia, blepharitis, or bacterial conjunctivitis: propensity score analyses. 62
34035495 2022
14
Strabismus Surgery: A Retrospective Comparison of Different Postoperative Treatment Regimes to Prevent Infections. 62
35472813 2022
15
Exploring community pharmacists' clinical decision-making using think aloud and protocol analysis. 62
33985891 2022
16
In-situ tear fluid dissolving nanofibers enable prolonged viscosity-enhanced dual drug delivery to the eye. 62
35085733 2022
17
Differential Diagnostic Challenges in the COVID-19 Pandemic: Renal Abscess After SARS-CoV-2 Infection in a Young Adolescent. 62
35279666 2022
18
Prevalence and Antimicrobial Resistance of Causative Agents to Ocular Infections. 62
35453215 2022
19
Clinical practice guidelines in multisystem inflammatory syndrome (MIS-C) related to COVID-19: a critical review and recommendations. 62
34982402 2022
20
Incidence of Bacterial and Nonbacterial Conjunctivitis in Patients With Atopic Dermatitis Treated With Dupilumab: A US Multidatabase Cohort Study. 62
35170520 2022
21
Preparation of NLCs-Based Topical Erythromycin Gel: In Vitro Characterization and Antibacterial Assessment. 62
35200497 2022
22
Bilateral, chronic, bacterial conjunctivitis in giant fornix syndrome. 62
35027379 2022
23
Ofloxacin-Loaded Niosome-Laden Contact Lens: Improved Properties of Biomaterial for Ocular Drug Delivery. 62
34851496 2021
24
Perspective on the clone library method for infectious diseases. 62
34400128 2021
25
Conjunctival Sac Microbiome in Infectious Conjunctivitis. 62
34683416 2021
26
Novel Chitosan-Coated Niosomal Formulation for Improved Management of Bacterial Conjunctivitis: A Highly Permeable and Efficient Ocular Nanocarrier for Azithromycin. 62
33940026 2021
27
Purulent Conjunctivitis and Progressive Corneal Stromal Necrosis. 62
34081098 2021
28
Incomplete Kawasaki Disease as Presentation of COVID-19 Infection in an Infant: A Case Report. 62
32756980 2021
29
Antimicrobial Susceptibility Patterns and Resistance Trends of Staphylococcus aureus and Coagulase-Negative Staphylococci Strains Isolated from Ocular Infections. 62
34063711 2021
30
Infection After Endoscopic Dacryocystorhinostomy: Incidence and Implications. 62
32938219 2021
31
Pharmacists' and pharmacy technicians' scopes of practice in the management of minor ailments at community pharmacies in Indonesia: a cross-sectional study. 62
34221196 2021
32
Influenza B infection and Kawasaki disease in an adolescent during the COVID-19 pandemic: a case report. 62
34231814 2021
33
Unraveling the Impact of Pneumococcal Conjugate Vaccines on Bacterial Conjunctivitis in Children. 62
32140700 2021
34
A Prospective, Population-based Study to Determine the Incidence and Bacteriology of Bacterial Conjunctivitis in Children <2 Years of Age Following 7-Valent and 13-Valent Pneumococcal Conjugate Vaccine Sequential Implementation. 62
32140705 2021
35
Antibacterial and COX-2 Inhibitory Tetrahydrobisbenzylisoquinoline Alkaloids from the Philippine Medicinal Plant Phaeanthus ophthalmicus. 62
33804446 2021
36
Quinolone immediate hypersensitivity due to topical ophthalmic preparations: a case report and review of literature. 62
33112013 2021
37
Using Historical Data to Support Approval of Drug Products for Ophthalmia Neonatorum: Innovative Approach Toward Evidence-Based Medicine. 62
33331874 2021
38
Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6. 62
34785887 2021
39
Expression levels of pro-inflammatory interleukin-8 and certain antimicrobial peptides in concurrent with bacterial conjunctivitis. 62
34012880 2021
40
Cohort profile: Study on Zika virus infection in Brazil (ZIKABRA study). 62
33400705 2021
41
A progressive and severe rash - Answers. 62
35072390 2021
42
Predominant role of Haemophilus influenzae in the association of conjunctivitis, acute otitis media and acute bacterial paranasal sinusitis in children. 62
33420151 2021
43
Antibacterial effects of antibiotics and cell-free preparations of probiotics against Staphylococcus aureus and Staphylococcus epidermidis associated with conjunctivitis. 62
33424249 2020
44
The in vitro efficacy of eye drops containing a bacteriophage solution specific for Staphylococcus spp. isolated from dogs with bacterial conjunctivitis. 62
33319700 2020
45
Reply to Comment on: A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis. 62
32826036 2020
46
Comment on: A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis. 62
32826035 2020
47
COVID-19 and Telehealth: Prevention of Exposure in a Medically Complex Patient With a Mild Presentation. 62
32593563 2020
48
Self-reported confidence with ocular examination and management of eye diseases by general medical practitioners. 62
32913165 2020
49
Parinaud's Oculoglandular Syndrome: A Case in an Adult with Flea-Borne Typhus and a Review. 62
32751142 2020
50
Conjunctivitis: A Systematic Review. 62
32864068 2020

Variations for Bacterial Conjunctivitis

Expression for Bacterial Conjunctivitis

Search GEO for disease gene expression data for Bacterial Conjunctivitis.

Pathways for Bacterial Conjunctivitis

Pathways related to Bacterial Conjunctivitis according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.25 TNF IL6 IL1B IL10 CXCL8 CD4
2
Show member pathways
13.23 TNF IL6 IL1B IL10 CXCL8 CD4
3
Show member pathways
12.58 TNF IL6 IL1B IL10 CXCL8
4
Show member pathways
12.55 TNF IL6 IL1B IL10 CD4
5
Show member pathways
12.46 TNF IL6 IL1B CXCL8
6
Show member pathways
12.36 CXCL8 IL1B IL6 TNF
7
Show member pathways
12.27 TNF IL6 IL1B CXCL8
8 12.11 TNF IL6 IL1B IL10 CXCL8
9 12.08 TNF IL6 IL1B IL10
10 11.97 TNF IL6 IL1B CXCL8
11 11.96 TNF IL6 IL10 CEACAM3 CD4
12 11.89 IL6 IL1B CXCL8
13 11.89 TNF IL6 IL1B IL10 CXCL8
14 11.87 CXCL8 IL10 IL1B TNF
15 11.84 IL6 IL10 CXCL8
16
Show member pathways
11.82 CD4 IL1B IL6
17 11.8 TNF IL1B IL10 CD4
18
Show member pathways
11.77 IL6 CXCL8 CRP CD4
19
Show member pathways
11.77 TNF IL6 IL1B IL10 CD4
20 11.75 TNF IL6 IL1B CXCL8
21 11.72 IL6 IL10 CD4
22 11.72 TNF IL6 IL10 CRP
23 11.67 IL6 IL1B CD4
24 11.67 IL6 IL10 CXCL8
25 11.66 CXCL8 IL1B IL6 TNF
26
Show member pathways
11.65 CXCL8 IL1B IL6 TNF
27 11.63 TNF IL6 IL10 CXCL8
28 11.62 TNF IL6 IL1B IL10
29
Show member pathways
11.59 TNF IL6 IL10
30 11.53 TNF IL10 CXCL8
31 11.52 TNF IL6 CXCL8
32 11.52 TNF IL6 IL1B IL10 CD4
33 11.46 IL1B IL6 TNF
34 11.32 IL10 IL1B IL6 TNF
35 11.3 TNF IL6 IL1B
36 11.18 TNF IL6 IL1B CXCL8
37 11.1 IL6 IL1B IL10
38 11.07 CXCL8 IL1B IL6 TNF
39 11.03 TNF IL6 IL1B IL10 CXCL8
40 10.97 TNF IL6 IL1B IL10 CXCL8
41 10.77 IL6 IL1B
42 10.74 TNF IL6 CXCL8 CRP
43 10.68 IL6 CXCL8
44 10.48 TNF IL6 IL1B IL10 CD4
45
Show member pathways
10.31 TNF IL6 CXCL8

GO Terms for Bacterial Conjunctivitis

Cellular components related to Bacterial Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.55 TNF NPPB IL6 IL1B IL10 GPT

Biological processes related to Bacterial Conjunctivitis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 defense response to Gram-positive bacterium GO:0050830 10.13 TNF IL6 IL1B CRP
2 positive regulation of DNA-binding transcription factor activity GO:0051091 10.11 TNF IL6 IL1B IL10
3 regulation of insulin secretion GO:0050796 10.06 TNF IL6 IL1B
4 response to activity GO:0014823 10.05 TNF IL6 IL10
5 cellular response to lipopolysaccharide GO:0071222 10.02 TNF IL6 IL1B IL10 CXCL8
6 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.01 IL10 IL6 TNF
7 positive regulation of chemokine production GO:0032722 9.97 TNF IL6 IL1B
8 immune response GO:0006955 9.96 TNF IL6 IL1B IL10 CXCL8 CNIH1
9 liver regeneration GO:0097421 9.95 IL10 IL6 TNF
10 negative regulation of neurogenesis GO:0050768 9.93 TNF IL6 IL1B
11 negative regulation of cytokine production involved in immune response GO:0002719 9.89 TNF IL10
12 positive regulation of glial cell proliferation GO:0060252 9.88 TNF IL6 IL1B
13 positive regulation of fever generation GO:0031622 9.86 TNF IL1B
14 sequestering of triglyceride GO:0030730 9.85 TNF IL1B
15 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.8 TNF IL1B
16 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.8 IL10 IL1B TNF
17 chronic inflammatory response to antigenic stimulus GO:0002439 9.73 TNF IL10
18 positive regulation of neuroinflammatory response GO:0150078 9.63 TNF IL6 IL1B
19 negative regulation of lipid storage GO:0010888 9.43 TNF IL6 CRP
20 vascular endothelial growth factor production GO:0010573 9.1 TNF IL6 IL1B

Molecular functions related to Bacterial Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.28 TNF IL6 IL1B IL10 CXCL8

Sources for Bacterial Conjunctivitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....